Immunocore Holdings plc has announced its strategic priorities for 2026, focusing on expanding the reach of KIMMTRAK (tebentafusp) to more metastatic uveal melanoma patients in the US and globally. The company plans to complete enrollment of the TEBE-AM Phase 3 trial in the first half of 2026, with topline results expected as early as the second half of the year. Immunocore also intends to present Phase 1/2 data from its PRAME franchise in the second half of 2026, including brenetafusp combination studies in ovarian and lung cancer and initial data for the half-life extended candidate IMC-P115C. Additional Phase 1 HIV data will be released in the second half of 2026. The company is preparing to dose the first patient in a Phase 1 type 1 diabetes trial in the first half of 2026 and aims to submit a clinical trial application for a second autoimmune candidate in the second half of the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-000780), on January 09, 2026, and is solely responsible for the information contained therein.